Key Takeaways
- Margin expansion is the core story, not revenue fireworks: EBITDA margin jumped to 20.75% in 9M FY26 from ~10% a year ago, driven by falling raw material costs and a mix shift toward registered export products. Management targets 22% for FY26 and 12-15%+ in FY27.
- The business model is being deliberately reshaped: Low-margin loan-license work (under 1% of sales) is being closed; domestic contract manufacturing will be held steady; the growth vector is merchant exports, where 100+ newly registered products are now commercial.
- Nigeria is the near-term catalyst, via a JV with Eurosun Pharmaceuticals: The partnership splits responsibilities (Curis manufactures, Eurosun markets) and targets Nigeria first, with 20+ products in registration. Nigeria revenue is expected to ramp from 0.5% to 5-10% of total revenue in FY27.
- Own-brand ambition is priced into the medium-term thesis but carries execution risk: Management aims for own-brand sales to reach 10% of total revenue in FY28 and 30% in FY29, with 40-50% EBITDA margins on that slice. The first own-brand launch is planned for Nigeria, but only after the JV establishes a 20% revenue base there.
- What to watch next quarter: Whether the Ghana audit (March/April) yields a certificate and initial orders; any firm capex or revenue guidance for FY27, which management gave conflicting signals on; and whether the injectable project moves from planning to a land application and license timeline.
Margin Transformation: Raw Materials & Registration
- The raw material windfall: Paracetamol prices fell from ₹800-900/kg to ₹400/kg, while finished-product selling prices were held at 2023 levels. That spread, combined with similar moves across other APIs, is the single largest driver of the margin expansion.
- Registration pipeline unlocked: Products submitted for registration in 2019 were delayed by COVID through 2021. The process restarted in 2022, and by FY24 more than 100 products were registered, with 50-70 now commercial. Registered products carry structurally higher margins than commoditized contract work.
- Sustainability hinges on mix, not raw materials: Management says the current margin level is sustainable into FY27 because own-brand sales (40-50% EBITDA margin) will begin layering in, offsetting any raw material normalization. The target is an EBITDA margin above 12-15% in FY27, rising to 15% when own-brand marketing starts in FY28.
- Working capital absorbed some of the gain: Inventory days rose sharply (from 115 to 347) as the company stopped loan-license manufacturing (where clients supplied materials) and made bulk purchases for discounts. Payable days fell from 360 to 112 under MSME 45-day payment rules. Both moves consumed cash even as margins improved.
Jaimik Patel: "if I'll take the average, it will be 50% or 40% EBITDA margin for that sales only which we will going to achieve 10% of our total revenue in 27-28."
Business Model Reshaping: Exit Low Margin, Enter Exports
- Loan license and job work being closed: These segments carried negligible margin and no growth, and were kept only to survive the early years. They now represent less than 1% of total sales and are being wound down.
- Domestic contract manufacturing held stable: Work for clients like JB Chemical, Cadila, and Troika carries fixed margins and will be maintained at current levels until Curis's own consumption capacity is fully utilized.
- Merchant export is the growth engine: The company targets a 30-40% increase in merchant export contract manufacturing next financial year, which would indirectly contribute 10-15% of total FY27 revenue. New country registrations (Ghana, Kenya, Tanzania) feed this pipeline.
- The 3,000-product ambition: Management has set a target to reach 3,000 registered products in a short period, a scale play that would widen the export funnel considerably.
Jaimik Patel: "contract manufacturing for loan license and job per sales, we are going to close it, because there is no much margin, is it, in that, and there is no growth of company in that, to move forward with that. That we were doing is to just, survive the company."
Nigeria JV: Structure, Timeline & Revenue Path
- Partnership mechanics: Eurosun Pharmaceuticals (5+ years in Nigeria, presence in Ghana, Kenya, Congo, and Latin America) handles marketing and distribution; Curis handles manufacturing and quality. Expenses and profits are split. Brand ownership is shared or solely Curis's.
- Registration underway: More than 20 products are now in registration for Nigeria, a process that takes roughly one year. Commercial sales begin only after registration is granted.
- Revenue ramp: Nigeria currently contributes roughly 0.5% of total revenue. Management expects that to reach 5-10% in FY27 and 20% thereafter, at which point Curis will introduce its own brand name in the country.
- Why Eurosun: The partner has visited Nigeria more than eight times, has 15+ years of experience, and already sells injectables (30-40% of its Nigeria mix), which Curis does not yet manufacture but plans to.
Own-Brand Strategy: The Long Margin Bet
- Phased introduction: Own-brand launch is sequenced after the JV establishes market presence. Nigeria comes first (once revenue hits 20% of total), then Kenya. Ghana own-brand is penciled for FY28 after a market-establishment year in FY27.
- Revenue targets: Own-brand sales are targeted at 10% of total revenue in FY28 and 30% in FY29. Only 1-2 of the initial 10 products are expected to deliver very high margins, but the average EBITDA margin on the own-brand slice is projected at 40-50%.
- The brand thesis: Management argues that pharmaceutical companies are recognized by their brand names (citing Troika/Dynapar, Ranbaxy/Volini), and that building a Curis brand in African markets is the path to a valuation re-rating. The stated ambition is to achieve 2-3 times the current valuation within 3-4 years.
- Execution fragility: The entire own-brand timeline depends on first building a merchant-export base in each country, then registering Curis-branded products (another 1-1.5 years), then winning shelf space against established brands. None of this is contracted today.
Jaimik Patel: "any pharmaceutical company, I don't know about the rich people, but if Pharma company, in Pharma people, they are recognized by their brand name only. Like, Troika is there, and then they are recognized by Dynapar brand name only. Ranbaxy was there, it was recognized by Volini Gel."
New Markets & Product Capabilities
- Ghana: An audit is expected in March or April 2025, with a certificate within 2-3 months of a successful audit (valid 3-4 years). Products will be introduced for registration immediately after, targeting merchant export sales first.
- Kenya and Tanzania: Kenya is in the pipeline for own-brand introduction after Nigeria; Tanzania is referenced as a country whose audit requirements are driving factory upgrades (epoxy flooring).
- Injectables: Management calls injectables essential ("without injectable, you cannot win any country") and has been working on the project for one year. The plan: apply for 5,000 sq meter land in GIDC, introduce vial, ampoule, and ready-mix injection (PMS) formats. Timeline: one year post-license for formula stabilization with zero commercial sales, then six months for order fulfillment.
- Oncology: Planned as a future capability, with management noting that Nigeria, Ghana, and Kenya have no domestic oncology manufacturing. No timeline was given.
Jaimik Patel: "without injectable, you cannot win any country."
Financial Position & Capex
- Fundraise deployed: Funds received in October 2025 have been used to repay secured loans and will be directed toward revenue growth.
- Factory investments planned: A new building alongside the existing one (without disrupting operations) will expand warehousing, stability chambers, and QC areas. Specific line items include ₹2.61 crores for testing columns, air-handling unit filters to reduce electricity costs, and epoxy flooring for audit readiness.
- Capex guidance is unclear: Management stated FY27 capex would be "same as last year, or maybe higher few times," a range too wide to model. Separately, an executive offered FY27 figures (₹55-60 Cr revenue, 22% EBITDA, 15-17% PAT) but another executive disclaimed knowledge of financials, leaving those numbers unconfirmed.
- Working capital need: Management cited ₹11 crore as the working capital required to achieve the planned revenue scale within one to two years.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue growth | 20% YoY, may increase due to October fundraise | FY26 closing |
| FY26 EBITDA margin | 22% (up from 20.75% in 9M) | FY26 closing |
| FY27 revenue growth | 20-25% YoY | FY27 |
| FY27 EBITDA margin | Above 12-15% | FY27 |
| Merchant export growth | 30-40% increase in contract manufacturing for merchant export | FY27 |
| Nigeria revenue share | Grow from ~0.5% to 5-10% of total revenue | FY27 |
| Own-brand revenue share | 10% of total revenue | FY28 |
| Own-brand revenue share | 30% of total revenue | FY29 |
| Ghana audit and certificate | Audit in March/April 2025; certificate within 2-3 months post-audit | Q4 FY26 / Q1 FY27 |
| Loan license / job work closure | Already stopped, less than 1% of sales | Effective immediately |
| Injectable project | Apply for 5,000 sqm land; one year stabilization post-license; six months to first orders | No start date given |
Key Metrics
| Metric | H1 FY26 / FY26 |
|---|---|
| Revenue (H1 FY26) | ₹27.91 cr (30 Sep 2025) |
| Revenue (FY25) | ₹50.27 cr |
| Revenue (FY24) | ₹35.97 cr |
| Revenue (FY23) | ₹35.83 cr (36% domestic, 63.78% export) |
| Revenue (9M FY26) | ₹42 cr (by 31 Dec 2025) |
| FY26 revenue growth expectation | 20%, may increase further |
| FY27 revenue guidance | ₹55–60 cr |
| FY27 revenue growth expectation | 20–25% |
| EBITDA margin (FY23) | 9.80% |
| EBITDA margin (FY24) | 23.65% |
| EBITDA margin (FY25) | 21.40% |
| EBITDA margin (FY26 TTM) | ~20.75% |
| FY26 EBITDA margin expectation | 22% |
| FY27 EBITDA margin guidance | 22% |
| PAT margin (FY23) | 5.23% |
| PAT margin (FY24) | 14.13% |
| PAT margin (FY25) | 12.35% |
| PAT (FY25) | ₹6.1 cr |
| FY26 PAT growth expectation | 20–30% hike |
| FY27 PAT margin guidance | 15–17% |
| FY27 PBT margin guidance | ~19% |
| Net worth (FY23) | 0.95% |
| Net worth (FY24) | 5.97% |
| Net worth (FY25) | 16.52% |
| Own-brand direct export share | <1% of total sales |
| Kenya share of sales | 20–30% |
| Nigeria share of sales (current) | ~0.5% of total revenue |
| Nigeria share of sales (FY27 expected) | 5–10% of total revenue |
| Contract manufacturing merchant export growth target (FY27) | 30–40% increase |
| Products developed | >1,200, targeting 3,000 |
| Annual product portfolio expansion | 20–30% |
| Inventory days (FY23) | 115 |
| Inventory days (FY25) | 347 |
| Payable days (Mar 2022) | 360 |
| Payable days (current) | 112 |
| IPO capex for factory upgrades | ₹2.61 cr |
| IPO working capital allocation | ~₹11 cr |
| Eurosun Nigeria standalone sales | >₹10 cr |
| Injectables project capex estimate | ₹50–55 cr (incl. 2 years expense) |
| Injectables land requirement | 4,000–5,000 sq m |